Press release
Soft Tissue Sarcoma Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Discover the latest drugs and treatment options in the Soft Tissue Sarcoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Soft Tissue Sarcoma Pipeline Outlook [https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Soft Tissue Sarcoma Marketed and Pipeline Drugs Report
* In May 2025, Adcendo ApS announced a Phase 1/2 study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma.
* In May 2025, ImmunoGenesis conducted a study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Advanced Soft Tissue Sarcoma. TH-302 is activated at lower oxygen concentrations than other bioreductive prodrugs (Duan 2008) and tirapazamine, a hypoxic cytotoxin that has been extensively studied in both preclinical and clinical studies.
* In May 2025, Epizyme Inc. organized a study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bones. Epithelioid sarcoma is an ultra-rare sarcoma of the soft-tissue.
* DelveInsight's Soft Tissue Sarcoma Pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Soft Tissue Sarcoma treatment.
* The leading Soft Tissue Sarcoma Companies such as Philogen S.p.A., Chipscreen Biosciences, Ltd, Lyvgen Biopharma Holdings Limited, Advenchen Laboratories, LLC, OncoTherapy Science, Inc, Philogen, Washington University School of Medicine, Sun Yat-sen University, QBiotics Group Limited, Thermosome GmbH, Intensity Therapeutics, Inc., Centre Leon Berard, Institut Claudius Regaud, Base Therapeutics and others.
* Promising Soft Tissue Sarcoma Pipeline Therapies such as Bevacizumab [Avastin], MGCD516, Pazopanib Hydrochloride, Liposomal Vincristine, AdAPT-001, Rubitecan, Ridaforolimus, OMBRABULIN (AVE8062), and others.
Stay ahead with the most recent pipeline outlook for Soft Tissue Sarcoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Soft Tissue Sarcoma Treatment Drugs [https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Soft Tissue Sarcoma Emerging Drugs Profile
* Fibronum + Doxorubicin: Philogen S.p.A.
Fibromun (L19TNF) is a fully-human immunomodulatory product consisting of the L19 antibody and TNF (a strong pro-inflammatory cytokine). (Recombinant TNF has so far been approved only for certain clinical applications.) The fusion of TNF to the L19 antibody specific to the EDB domain of fibronectin results in a tumor-targeted product, which selectively localizes at the site of disease, while sparing healthy organs. Fibromun has shown potent anti-tumor activity, both as single agent and in combination with other drugs, in several immunocompetent preclinical models inducing in most cases long-lasting complete responses. Currently, the drug is in Phase III stage of its development for the treatment of Soft Tissue Sarcoma.
* Chiauranib: Chipscreen Biosciences, Ltd
Chiauranib, a highly selective Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor, was developed by Chipscreen Biosciences specifically to address drug resistance. Chiauranib exerts a comprehensive anti-tumor effect by a triple-pathway mechanism that simultaneously inhibits tumor angiogenesis, prevents tumor cell mitosis, and modulates the tumor microenvironment. With a favorable safety profile, Chiauranib has outperformed drugs with a similar mechanism in its pharmacodynamic activity in animal studies.Currently, the drug is in Phase II stage of its development for the treatment of Soft Tissue Sarcoma.
* LVGN6051 and Anlotinib: Lyvgen Biopharma Holdings Limited
Exlinkibart (LVGN6051) is a Anti-CD137/4-1BB agonistic monoclonal antibody and xLinkAb conditional 4-1BB agonistic monoclonal antibody with selective Fc-receptor IIB binding for targeted immune activation in the tumor microenvironment. LVGN6051 has achieved RP2D of 4 mg/kg Q3W, showing desirable PK and PD properties, acceptable safety profile and durable objective responses in heavily pre-treated patients with various solid tumors. Upon administration, anti-CD137 agonistic antibody LVGN6051 binds to and activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytokine production and promotes T-cell mediated anti-tumor immune responses. Registration clinical trials of exlinkibart in melanoma, sarcoma and head and neck cancers are planned. Currently, the drug is in Phase I/II stage of its development for the treatment of Soft Tissue Sarcoma.
The Soft Tissue Sarcoma Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Soft Tissue Sarcoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Soft Tissue Sarcoma Treatment.
* Soft Tissue Sarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Soft Tissue Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Soft Tissue Sarcoma market
Explore groundbreaking therapies and clinical trials in the Soft Tissue Sarcoma Pipeline. Access DelveInsight's detailed report now! @ New Soft Tissue Sarcoma Drugs [https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Soft Tissue Sarcoma Companies
Philogen S.p.A., Chipscreen Biosciences, Ltd, Lyvgen Biopharma Holdings Limited, Advenchen Laboratories, LLC, OncoTherapy Science, Inc, Philogen, Washington University School of Medicine, Sun Yat-sen University, QBiotics Group Limited, Thermosome GmbH, Intensity Therapeutics, Inc., Centre Leon Berard, Institut Claudius Regaud, Base Therapeutics and others.
Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
Soft Tissue Sarcoma Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Unveil the future of Bronchiectasis Treatment. Learn about new Soft Tissue Sarcoma Marketed and Drugs Developments, and key companies with DelveInsight's expert analysis @ Bronchiectasis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Soft Tissue Sarcoma Pipeline Report
* Coverage- Global
* Soft Tissue Sarcoma Companies- Philogen S.p.A., Chipscreen Biosciences, Ltd, Lyvgen Biopharma Holdings Limited, Advenchen Laboratories, LLC, OncoTherapy Science, Inc, Philogen, Washington University School of Medicine, Sun Yat-sen University, QBiotics Group Limited, Thermosome GmbH, Intensity Therapeutics, Inc., Centre Leon Berard, Institut Claudius Regaud, Base Therapeutics and others.
* Soft Tissue Sarcoma Pipeline Therapies- Bevacizumab [Avastin], MGCD516, Pazopanib Hydrochloride, Liposomal Vincristine, AdAPT-001, Rubitecan, Ridaforolimus, OMBRABULIN (AVE8062), and others.
* Soft Tissue Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Soft Tissue Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Soft Tissue Sarcoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Soft Tissue Sarcoma Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Soft Tissue Sarcoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Soft Tissue Sarcoma - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Fibronum + Doxorubicin: Philogen S.p.A.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Chiauranib: Chipscreen Biosciences, Ltd
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* LVGN6051 and Anlotinib: Lyvgen Biopharma Holdings Limited
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Soft Tissue Sarcoma Key Companies
* Soft Tissue Sarcoma Key Products
* Soft Tissue Sarcoma- Unmet Needs
* Soft Tissue Sarcoma- Market Drivers and Barriers
* Soft Tissue Sarcoma- Future Perspectives and Conclusion
* Soft Tissue Sarcoma Analyst Views
* Soft Tissue Sarcoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=soft-tissue-sarcoma-pipeline-appears-robust-with-70-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/soft-tissue-sarcoma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Soft Tissue Sarcoma Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4024317 • Views: …
More Releases from ABNewswire
Rising Demand for Personal Injury Legal Services Amid Increasing Accident Claims
In many situations, negotiations with insurance companies are pursued before court proceedings are considered. Personal injury attorneys often act as intermediaries in these discussions, ensuring that offers are fairly assessed in relation to the damages sustained. If satisfactory agreements cannot be reached, the matter is presented before a court, where a judge or jury determines the outcome.
Personal injury law has been regarded as one of the most vital areas within…
Growing Awareness of Injury Risks Elevates Role of Car Accident Doctor
As awareness of accident-related injuries grows, Boise residents are taking a more proactive approach to their health following collisions.
Recovering from an auto accident involves more than just vehicle repairs-it also means addressing the physical injuries that often go unnoticed at first. For this reason, the role of a car accident doctor [https://www.pricechiropracticcenter.com/#:~:text=3-,Car%20Accident,-Have%20you%20been] has become increasingly important. In Boise, ID, more residents are realizing the long-term health risks associated with untreated…
Dog Grooming Standards Strengthened to Ensure Pet Health and Safety
In recent years, the importance of dog grooming has grown significantly, with veterinary professionals and pet owners alike recognizing its role in overall animal wellness.
Ensuring the health and happiness of pets requires much more than love and care at home-it also depends on professional grooming practices that meet the highest safety standards. In recent years, the importance of dog grooming [https://www.normandyblvdanimalhospital.com/#:~:text=lifespan%20of%20your-,dog,-or%20cat%20with] has grown significantly, with veterinary professionals and pet owners…
Transportation Management System Market Growth Drivers, Emerging Trends, Opportu …
Transportation Management System Market by Solutions (Planning & Execution, Order Management, Analytics & Reporting, Routing & Tracking), Transportation Mode (Roadways, Railways, Airways, Maritime), and End User - Global Forecast to 2030.
The Transportation Management System Market [https://www.marketsandmarkets.com/Market-Reports/transportation-management-market-232446179.html?utm_campaign=transportationmanagementmarket&utm_source=abnewswire.com&utm_medium=paidpr] is expected to increase at a 14.9% compound annual growth rate (CAGR) from USD 18,503.2 million in 2025 to USD 37,036.8 million by 2030. For many businesses, transportation represents a substantial cost component. Through…
More Releases for Sarcoma
Emerging Trends Influencing The Growth Of The Sarcoma Drugs Market:Innovative Ge …
The Sarcoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Sarcoma Drugs Market Size Expected to Be by 2034?
The Sarcoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034.…
Key Influencer in the Sarcoma Drugs Market 2025: Surging Soft Tissue Sarcoma Cas …
What combination of drivers is leading to accelerated growth in the sarcoma drugs market?
The sarcoma drugs market is projected to grow due to an increase in soft tissue sarcoma cases. Soft tissue sarcoma is a type of cancer that originates in the body's soft tissues, such as muscles, fats, tendons, lymph, and nerves. Sarcoma drugs, widely utilized in the healthcare sector, treat bone and soft tissue sarcoma by targeting cancer…
Sarcoma Drugs Market Report 2024 - Sarcoma Drugs Market Growth, Trends, And Fore …
"The Business Research Company recently released a comprehensive report on the Global Sarcoma Drugs Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The sarcoma drugs market size…
Alveolar Soft Part Sarcoma Market - Unleashing Progress: Alveolar Soft Part Sarc …
Newark, New Castle, USA: The "Alveolar Soft Part Sarcoma Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Alveolar Soft Part Sarcoma Market: https://www.growthplusreports.com/report/alveolar-soft-part-sarcoma-market/8620
This latest report researches the…
Kaposi Sarcoma Treatment Market Drivers
Increasing number of patients undergoing organ transplant procedures is the leading cause for growth of the Kaposi sarcoma treatment market, as patients undergoing organ transplants are highly susceptible to this cancer. For instance, according to the National Kidney Foundation (NKF), in 2014, 17,107 kidney transplants took place in the U.S. Among which, 11,570 came from deceased donors and 5,537 came from living donors. Furthermore, increasing incidence of HIV/AIDS-associated Kaposi sarcoma…
Kaposi Sarcoma Market Research Report 2024
The global Kaposi sarcoma (KS) market is immensely consolidated and the top two players, namely Johnson & Johnson and Merck & Co. Inc. accounted for almost 50% of the overall market in 2015. The contribution of domestic players such as Sun Pharmaceutical Industries Limited is presented low. However, Transparency Market Research predicts that the contribution of these companies will increase during the forecast period owing to the patent expiry of…
